Skip Nav Destination
Issues
1 October 2014
-
Cover Image
Cover Image
Functional and acquired characteristics of the early pre-cancer phenotype are intrinsically different from those of a more advanced anaplastic or invasive malignancy. The biologic conversion of premalignancy to invasive disease is complex and is likely to influence delivery of nanoparticles (grey circles) to tumors. Intraepithelial neoplasia (IEN) are early pre-cancerous lesions (pink cells) that proliferate until the normal basement membrane is breached by cancerous cells (brown cells). Switching on angiogenesis and chronic inflammation involving the accumulation of proinflammatory, stromal, and blood factors can dilate blood vessels and alter pericyte (green cells) behavior. Elevated hypoxia and apoptosis (condensed yellow cells) further increase vessel leakiness. Angiogenic sprouting and tip cell (elongated yellow cells) driven angiogenesis leads to further recruitment of additional cells during the angiogenic switch. See article by Menter and colleagues (beginning on page 973) for more information. - PDF Icon PDF LinkTable of Contents
ISSN 1940-6207
EISSN 1940-6215
Issue Sections
Commentary
Review
Research Articles
Breast Cancer Risk in Young Women in the National Breast Screening Programme: Implications for Applying NICE Guidelines for Additional Screening and Chemoprevention
D. Gareth Evans; Adam R. Brentnall; Michelle Harvie; Sarah Dawe; Jamie C. Sergeant; Paula Stavrinos; Susan Astley; Mary Wilson; John Ainsworth; Jack Cuzick; Iain Buchan; Louise S. Donnelly; Anthony Howell
Analysis of DNA Methylation in Bowel Lavage Fluid for Detection of Colorectal Cancer
Taku Harada; Eiichiro Yamamoto; Hiro-o Yamano; Masanori Nojima; Reo Maruyama; Kohei Kumegawa; Masami Ashida; Kenjiro Yoshikawa; Tomoaki Kimura; Eiji Harada; Ryo Takagi; Yoshihito Tanaka; Hironori Aoki; Masayo Nishizono; Michiko Nakaoka; Akihiro Tsuyada; Takeshi Niinuma; Masahiro Kai; Kazuya Shimoda; Yasuhisa Shinomura; Tamotsu Sugai; Kohzoh Imai; Hiromu Suzuki
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.